Myriad Genetics Sees Unusually Large Options Volume (MYGN)
Shares of Myriad Genetics (NASDAQ:MYGN) was the target of unusually large options trading activity on Wednesday. Traders acquired 6,637 put options on the stock, AnalystRatingsNetwork.com reports. This is an increase of approximately 117% compared to the typical volume of 3,063 put options.
A number of research firms have recently commented on MYGN. Analysts at Ladenburg Thalmann upgraded shares of Myriad Genetics (NASDAQ:MYGN) from a “neutral” rating to a “buy” rating in a research note to investors on Tuesday. They now have a $28.00 price target on the stock. Separately, analysts at Ned Davis Research downgraded shares of Myriad Genetics (NASDAQ:MYGN) from a “buy” rating to a “neutral” rating in a research note to investors on Monday. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Myriad Genetics (NASDAQ:MYGN) in a research note to investors on Thursday, September 19th. They now have a $27.00 price target on the stock. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have issued a buy rating to the company’s stock. Myriad Genetics currently has an average rating of “Hold” and a consensus price target of $34.00.
Myriad Genetics (NASDAQ:MYGN) traded down 2.17% during mid-day trading on Wednesday, hitting $24.76. The stock had a trading volume of 2,152,155 shares. Myriad Genetics has a 1-year low of $22.61 and a 1-year high of $38.27. The stock’s 50-day moving average is $26.56 and its 200-day moving average is $28.42. The company has a market cap of $1.992 billion and a P/E ratio of 14.30.
Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $0.53 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.09. The company had revenue of $174.10 million for the quarter, compared to the consensus estimate of $159.87 million. During the same quarter in the previous year, the company posted $0.34 earnings per share. The company’s revenue for the quarter was up 30.9% on a year-over-year basis. Analysts expect that Myriad Genetics will post $1.91 EPS for the current fiscal year.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.